AU2001275530A1 - Inhibitors of c-reactive protein induced inflammation - Google Patents

Inhibitors of c-reactive protein induced inflammation

Info

Publication number
AU2001275530A1
AU2001275530A1 AU2001275530A AU7553001A AU2001275530A1 AU 2001275530 A1 AU2001275530 A1 AU 2001275530A1 AU 2001275530 A AU2001275530 A AU 2001275530A AU 7553001 A AU7553001 A AU 7553001A AU 2001275530 A1 AU2001275530 A1 AU 2001275530A1
Authority
AU
Australia
Prior art keywords
inhibitors
reactive protein
induced inflammation
protein induced
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001275530A
Other languages
English (en)
Inventor
Vincenzo Pasceri
James T Willerson
Edward T. H. Yeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of AU2001275530A1 publication Critical patent/AU2001275530A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
AU2001275530A 2000-06-08 2001-06-08 Inhibitors of c-reactive protein induced inflammation Abandoned AU2001275530A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21041500P 2000-06-08 2000-06-08
US60/210,415 2000-06-08
PCT/US2001/040941 WO2001094951A2 (en) 2000-06-08 2001-06-08 Inhibitors of c-reactive protein induced inflammation

Publications (1)

Publication Number Publication Date
AU2001275530A1 true AU2001275530A1 (en) 2001-12-17

Family

ID=22782810

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001275530A Abandoned AU2001275530A1 (en) 2000-06-08 2001-06-08 Inhibitors of c-reactive protein induced inflammation

Country Status (5)

Country Link
US (1) US6764826B2 (ja)
JP (1) JP2003536075A (ja)
AU (1) AU2001275530A1 (ja)
CA (1) CA2411139A1 (ja)
WO (1) WO2001094951A2 (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7390795B2 (en) 2000-12-18 2008-06-24 Pentraxin Therapeutics Limited Treatment and prevention of tissue damage
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US7425545B2 (en) * 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
AU2003212850A1 (en) * 2002-02-01 2003-09-02 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cardiovascular disease
GB0211136D0 (en) * 2002-05-15 2002-06-26 Univ London Treatment and prevention of tissue damage
NZ539624A (en) * 2002-09-27 2008-08-29 Martek Biosciences Corp Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
CA2538078C (en) * 2003-09-25 2012-12-04 Activbiotics, Inc. Rifalazil formulations
US7226995B2 (en) * 2003-10-23 2007-06-05 Stc.Unm Use of C-reactive protein to treat immune complex-mediated renal disease
WO2005058359A2 (en) * 2003-12-15 2005-06-30 Theralogic Gmbh & Co. Kg Method for neutralizing effects of crp for increasing immune reactions to hiv
WO2005070409A1 (en) * 2004-01-21 2005-08-04 Medvet Science Pty Ltd A method of modulating pro-inflammatory and inflammatory activity mediated by c-reactive protein
US20060020043A1 (en) * 2004-07-26 2006-01-26 Roger Berlin Methods and compositions for reducing C-reactive protein
EP1835928A2 (en) * 2004-12-22 2007-09-26 Rheoscience A/S Mas related g protein coupled receptors as drug targets
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
CA3086149A1 (en) 2006-04-04 2007-10-11 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
US7642062B2 (en) * 2006-12-29 2010-01-05 Avon Products Inc. Compositions and methods of their use for improving the condition and appearance of skin
JP2010516258A (ja) * 2007-01-20 2010-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ反応性タンパク質（ｃｒｐ）ノックアウトマウス
WO2010144358A1 (en) 2009-06-08 2010-12-16 Singulex, Inc. Highly sensitive biomarker panels
DK2549995T3 (da) * 2010-03-23 2021-05-25 Philip Morris Products Sa Brug af anatabin til behandling af inflammation og metoder til syntetisering af anatabin

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221605A (en) * 1984-10-31 1993-06-22 Igen, Inc. Luminescent metal chelate labels and means for detection
US5238808A (en) * 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
US5284760A (en) * 1989-04-03 1994-02-08 Feinstone Stephen M Techniques for producing site-directed mutagenesis of cloned DNA
US5500345A (en) 1989-04-25 1996-03-19 Iatron Laboratories, Inc. Hybridomas producing monoclonal antibodies specific for C-reactive protein and methods for detection of C-reactive protein
US5658772A (en) * 1989-12-22 1997-08-19 E. I. Du Pont De Nemours And Company Site-specific recombination of DNA in plant cells
US5149797A (en) * 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5220007A (en) * 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
DE69112207T2 (de) * 1990-04-05 1996-03-28 Roberto Crea "walk-through"-mutagenese.
US5380721A (en) * 1990-09-10 1995-01-10 Sterling Winthrop Inc. Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents
ATE137151T1 (de) * 1992-04-12 1996-05-15 Elpatronic Ag Verfahren und vorrichtung zum schweissen von blechen zu platinen mittels laser
US5389514A (en) * 1992-08-28 1995-02-14 Fox Chase Cancer Center Method for specifically altering the nucleotide sequence of RNA
US5527695A (en) * 1993-01-29 1996-06-18 Purdue Research Foundation Controlled modification of eukaryotic genomes
AU2646295A (en) 1994-05-18 1995-12-05 Ligand Pharmaceuticals, Inc. Screening for cytokine modulators
US5789166A (en) * 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
EP0931263A1 (en) * 1996-09-06 1999-07-28 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Method of screening for side effects of anticonceptives or estrogen and/or progesterone replacements or supplements
US6190670B1 (en) * 1999-04-12 2001-02-20 Immtech International Inc. Use of mCRP to enhance immune responses

Also Published As

Publication number Publication date
US20020142283A1 (en) 2002-10-03
US6764826B2 (en) 2004-07-20
WO2001094951A9 (en) 2003-02-13
JP2003536075A (ja) 2003-12-02
WO2001094951A2 (en) 2001-12-13
WO2001094951A3 (en) 2002-07-18
CA2411139A1 (en) 2001-12-13

Similar Documents

Publication Publication Date Title
AU2002213485A1 (en) Inhibitors of protein kinases
AU2001275530A1 (en) Inhibitors of c-reactive protein induced inflammation
AU2001282009A1 (en) Non-steroidal inflammation inhibitors
PL374221A1 (en) Antibody inhibitors of gdf-8 and uses thereof
AU2002316137A1 (en) Method of determining protein interaction inhibitors
AU2002339348A1 (en) Inhibition of STAT-1
AU2002243402A1 (en) Inhibitors of histone deacetylase
AU2001258771A1 (en) -secretase inhibitors
AU2001239791A1 (en) Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production
AUPR392301A0 (en) Protein phosphatase inhibitors
AU2001270260A1 (en) 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
AU2002230385A1 (en) Peptide deformylase inhibitors
AU2001247882A1 (en) Tricyclic protein kinase inhibitors
AU2576501A (en) Protein kinase inhibitors
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
AU2002214286A1 (en) Method of profiling protein
AU2002338734A1 (en) Use of phosphorodiesterase IV inhibitors
AU2002224550A1 (en) Corrosion inhibitors
AU5673099A (en) Inhibitors of amyloid formation
AU2002365928A1 (en) Inhibitors of autoinducer transporters
AU2002214038A1 (en) Inhibitors of transglutaminases
AU2003258941A1 (en) Metalloproteinase inhibitors and intermediates for preparation thereof
AU2002218084A1 (en) Inhibitors of thromboxane formation and action
AU2002305868A1 (en) Inhibitors of reggamma
AU2002221882A1 (en) Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors